Therapy in primary mediastinal B-cell lymphoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
   Trial
2. [Lymphomas in children and adolescents].Pathologie (Heidelberg, Germany) · 2023
   Review
3. Primary mediastinal/thymic diffuse large B-cell lymphoma: a population-based study on incidence and survival.Annals of hematology · 2023
   Article
4. Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.Haematologica · 2021
   Article
5. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.Cancers · 2021
   Article
6. Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents.Blood advances · 2019
   Article
7. How I treat primary mediastinal B-cell lymphoma.Blood · 2018
   Review
8. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies.Hematology. American Society of Hematology. Education Program · 2017
   Review
9. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.British journal of haematology · 2017
   Article
10. Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.Blood advances · 2017
    Review
11. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.BMC cancer · 2017
    Article
12. Management of Non-Hodgkin Lymphoma: ICMR Consensus Document.Indian journal of pediatrics · 2017
    Review
13. Primary mediastinal large B-cell lymphoma in Japanese children and adolescents.International journal of hematology · 2017
    Article
14. Non-Hodgkin Lymphoma in Children.Current hematologic malignancy reports · 2015
    Review
15. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Blood · 2015
    Review
16. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.Haematologica · 2014
    Article
17. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Review
18. Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.Oncology (Williston Park, N.Y.) · 2014
    Review

Corrections and comments

• Commented on by
  Therapy in primary mediastinal B-cell lymphoma.2013
• Comment on
  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.2013

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as